A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

Randomized controlled single blind prospective comparative study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: ORIYOMI OMOTOYOSI AKINYOTU
• Collaborator: University of Ibadan
• Treatments: Fanasil, pyrimethamine drug combination; Mefloquine; Pyrimethamine; Sulfadoxine

Criteria

Inclusion Criteria:

• Pregnant HIV positive patients

• Gestational age 16 weeks and above

• No history of use of Mefloquine or Sulphadoxine

• Pyrimethamine four weeks prior to recruitment.

Exclusion Criteria:

• Anaemia packed cell volume less than 30%

• Pre -existing medical conditions- Diabetes Mellitus, -Hypertension

• Allergy to Sulphadoxine- Pyrimethamine or Mefloquine

• Non-consenting patients

• Multiple gestation

• Known psychiatric illness

• Known seizure disorder

• History of severe renal or hepatic disease